Neuroendocrine Tumors Clinical Trials

Browse current & upcoming clinical research / studies on Neuroendocrine Tumors. There are a total of 53 clinical trials for Neuroendocrine Tumors in 10 countries with 5 trials currently in the United States. 17 are either active and/or recruiting patients or have not yet been completed. Click the title of each study to get the complete details on eligibility, location & other facts about the study.

Other clinical trials

Interventional trials
Determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments.
Observational trials
Address health issues in large groups of people or populations in natural settings.
Participants are currently being recruited and enrolled.
Active, not recruiting
Study is ongoing (i.e., patients are being treated or examined), but enrollment has completed.
Not yet recruiting
Participants are not yet being recruited or enrolled.
Enrolling by invitation
Participants are being (or will be) selected from a predetermined population.
The study has concluded normally; participants are no longer being examined or treated (i.e., last patient's last visit has occurred).
Study halted prematurely, prior to enrollment of first participant.
Recruiting or enrolling participants has halted prematurely but potentially will resume.
Recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated.
May 2015 - June 2018
Participants in this research study have tumors that express somatostatin receptors such as neuroendocrine tumors, medulloblastoma, meningioma, and neuroblastoma. Approximately 64 people will participate in this study conducted at the University of Iowa.
Sponsor: University of Iowa
Study type: Interventional
May 2015 - December 2016
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are unable to receive standard treatment.
Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Study type: Interventional
April 2015 - December 2019
Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs.
Sponsor: North Shore Long Island Jewish Health System
Study type: Interventional
February 2015 -
The goal of this clinical research study is to learn if cabozantinib can help to control advanced or metastatic pheochromocytoma or paraganglioma. The safety of this drug will also be studied.
Sponsor: M.D. Anderson Cancer Center
Study type: Interventional
February 2015 - April 2018
The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Study type: Interventional
January 2015 -
The purpose of this study is to see how a new tracer named 18F-MFBG (Meta Fluorobenzyl Guanidine) behaves in the body after injection, how it spreads to all the organs and how it is removed from the body. We will also study how long 18F-MFBG lasts in the blood after administered. In addition we want to study if 18F-MFBG can show Neuroendocrine tumors on a PET-CT scan.
Sponsor: Memorial Sloan Kettering Cancer Center
Study type: Interventional
December 2014 - September 2021
Background: - Neuroendocrine tumors (NETs) come from cells of the hormonal and nervous systems. Some people have surgery to shrink the tumor. Sometimes the tumors come back. Researchers think that treatment with drugs based on knowing the defective gene might give better results. Objective: - To see if drugs selected based on the defective gene result in better tumor response. The drugs are sunitinib and everolimus. Eligibility: - People age 18 and older with an advanced low- or intermediate-grade gastrointestinal or pancreatic neuroendocrine tumor. Design: - Participants will be screened with: < TAB> - Medical history < TAB> - Physical exam < TAB> - Scans < TAB> - Blood, urine, and lab tests - The study team will see if participants should have surgery. - If yes, participants will: - Sign a separate consent - Have CT scan before and after surgery - Have as much of the tumor removed as possible. A small piece will be tested for mutation type. - If no, participants will have a small piece of tumor removed for the testing. - If the surgery might cure them, the participant will leave the study. The other participants will be assigned to take either sunitinib or everolimus. - Participants will take their drug by mouth once a day. They will keep a medicine diary. Some will keep track of their blood pressure at least weekly. - Screening tests may be repeated at study visits. Participants also may have their heart evaluated. - About 30 days after the last day of their study drug, participants will have a follow-up visit that repeats the screening tests. - Participants will be contacted every 3 months after this visit.
Sponsor: National Institutes of Health Clinical Center (CC)
Study type: Interventional
December 2014 - December 2017
This study plans to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of response to treatment in patients with Somatostatin receptor expressing tumors who undergo imaging with a clinical indication. The investigators will conduct a study for 68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors. 68Ga-DOTATOC will be used in diagnostic assessment of patients with known or suspected NETs for whom there is an appropriate standard clinical indication for 68Ga-DOTATOC PET/CT either at staging or during follow up.
Sponsor: Mount Sinai School of Medicine
Study type: Interventional
October 2014 - December 2017
a multicenter, open-label phase Ib study to determine the safety, tolerability and preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine tumors
Sponsor: Hutchison Medipharma Limited
Study type: Interventional
September 2014 - September 2015
Through the investigators involvement in an international consortium, the investigators had the opportunity to acquire a new type of synthetizer for the radiolabelling of such tracers. The investigators propose in this project to develop on their site, the radiosynthesis of 68Ga-DOTATOC and to evaluate prospectively the diagnosis of neuroendocrine tumors, compared with the current imaging OctreoScan®. The objectives of this project are: - to validate the radiosynthesis of 68Ga-DOTATOC on their site with a new synthetizer - and clinically evaluate, through a prospective preliminary study, the diagnostic accuracy of PET-CT with 68Ga-DOTATOC in comparison with other standard imaging examinations.
Sponsor: University Hospital, Bordeaux
Study type: Observational
Home  •  Browse by Condition  •  Search Clinical Trials
The information found on this site has been provided by in accordance with their terms & conditions. Neither we (, the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.